Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Halozyme Therapeutics CEO sells $2.59 million in stock By Investing.com
Halozyme Therapeutics CEO Helen Torley sold 39,000 shares of common stock for approximately $2.59 million on April 1st and 2nd, 2026, while also exercising options to acquire 40,000 shares. Despite the insider sale, InvestingPro analysis suggests the stock is undervalued, boasting a strong return on equity and a P/E ratio of 24.91. These transactions occurred amidst significant news for the company, including a 52% increase in Q4 revenue, an interim CFO appointment, and FDA approval for a Johnson & Johnson therapy involving Halozyme’s DARZALEX FASPRO.